No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.
Dorado
Pedro
P
Berecz
Roland
R
Peñas-Lledó
Eva M
EM
de la Rubia
Alfredo
A
Llerena
Adrián
A
D000483:Alleles; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019388:Cytochrome P-450 CYP1A2; D003647:Debrisoquin / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005838:Genotype; D006801:Humans; D001523:Mental Disorders; D008653:Mesoridazine / Q000097:blood*; D010640:Phenothiazines / Q000097:blood*; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D012907:Smoking; D013881:Thioridazine / Q000008:administration & dosage / Q000493:pharmacokinetics*
D014150:Antipsychotic Agents; D010640:Phenothiazines; D008653:Mesoridazine; C040634:sulforidazine; D019388:Cytochrome P-450 CYP1A2; D013881:Thioridazine; D003647:Debrisoquin